Since its founding in 2015, XtalPi Inc. (XtalPi Holdings-P, XTALPI-P, stock code: 2228.HK) has maintained relentless R&D investments, driving technological and industrial innovation through deep integration of foundational science and cutting-edge technologies. These efforts have yielded significant results across biopharmaceuticals, fine chemicals, and renewable energy sectors, marking new milestones in the company’s growth and ushering in a new era.
Recently, XtalPi has been honored with several major awards, earning further acclaim from industry peers and beyond.
2024 Hurun China Top 50 AI Companies
Renowned research firm Hurun Research Institute released the inaugural “2024 Hurun China Top 50 AI Companies” list, ranking enterprises by valuation. XtalPi earned a spot through its breakthroughs in AI technology innovation and industrial applications.
The list spotlights China’s most valuable AI firms, evaluating their technological innovation, commercialization capabilities, and market performance to celebrate pioneers driving industry transformation.
FinanceAsia 2024 Achievement Awards
The prestigious English-language financial magazine Asian Finance announced the 2024 Achievement Awards, where XtalPi received the Highly Recommended Award for Best IPO of the Year.
Known as Asia’s leading capital markets monthly, Asian Finance wields significant influence in investment circles. Its annual awards are among the most authoritative in the Asia-Pacific, honoring major financial transactions and key players’ accomplishments in the region.
BioCentury-BayHelix Annual Awards
At the 11th China Healthcare Summit, co-hosted by BioCentury and BayHelix with McKinsey support, the BioCentury-BayHelix Annual Awards were unveiled. XtalPi clinched the Commercial Achievement of the Year award.
These awards recognize outstanding individuals and companies shaping China’s healthcare ecosystem, spanning categories like Research Achievement of the Year, Best Deal of the Year, Best Company of the Year, and Outstanding Female Leader of the Year.
R&D Guest 2024 IPO Award
During the 8th R&D Guest Clinical Conference and ChinaTrials16, leading industry media R&D Guest revealed its 2024 awards, including Outstanding Clinical Operations Team, Emerging Biotech, Innovative Drug, IPO, Deal, and Collaboration of the Year.
XtalPi secured the IPO of the Year award, sharing the stage with luminaries like Lilly China, Roche, Boehringer Ingelheim, and Legend Biotech—trailblazers in China’s healthcare and innovative drug landscape.
Greater Bay Area Data Application Innovation Competition
On the product front, XtalPi’s AI drug patent extraction and analysis platform, PatSight—developed in partnership with the Greater Bay Area Digital Economy Research Institute—stood out among 400 national teams, winning second prize in the specialized category (first in biopharma).
2024 Hurun U40 China Entrepreneurial Pioneers
Hurun Research Institute recently published the “2024 Hurun U40 China Entrepreneurial Pioneers” list, its second edition spotlighting China’s under-40 trailblazers. XtalPi Co-Founders Dr. Ma Jian and Dr. Lai Lipeng both made the cut.
